Our Opinion
Neos Therapeutics, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
Supporting Evidence:
The company announced that the U.S. Food and Drug Administration (FDA) approved Adzenys XR-ODT™ for the treatment of ADHD in patients six years and older.
“Use only if the potential benefit justifies the potential risk to the fetus. Based on animal data, Adzenys XR-ODT may cause fetal harm.” Read the following article
Company Description
Neos Therapeutics, Inc. operates as a pharmaceutical company, which engages in developing, manufacturing, and commercializing products using proprietary, extended-release drug delivery technology platform. It uses this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. The company was founded on June 15, 2009 and is headquartered in Grand Prairie, TX. [Source: MarketWatch]
Company Website: http://www.neostx.com